Julie Lellouche, Author at Labiotech.eu

About

Blogger for Labiotech.eu. Entrepreneurial Student at SupBiotech, Paris Higher Biotechnology Institute.

Articles by Julie Lellouche

News and Trends 9 Dec 2015

Here are the 6 Healthcare Disruptors We met in Paris

How can and will Healthcare be disrupted? This is an important question addressed at an event on Differential Medicine at ‘TheFamily‘ VC in Paris. On the 3rd and 4th December, I attended the Differential Medicine conference in Paris at the ‘The Family‘ HQ (an entrepreneurial VC). Here I give an overview of some of the […]

December 9, 2015 - 6 minutesmins - By Julie Lellouche

swissmedic newron xadago zambon parkinsons

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease. Zambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern […]

November 16, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 2 Nov 2015

A Glimpse into the DIY Biotech Movement: Biohacking, Vegan Cheese, Algae Beer and Bacterial Art!

Fab Labs have become hugely fashionable since 2010… But what about Bio Fab Labs? Have you ever thought about sharing your RNA or DNA amplification equipment? It can be a massive help for entrepreneurs or students, and Bio Fab Labs are starting to emerge in backyards across the world for Education, Innovation and even creative SynBio art. This new era of DIY […]

November 2, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment. Affimed Therapeutics is a NASDAQ-listed biotech […]

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 28 Sep 2015

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

Nestlé Institute of Health Sciences (NIHS) is teaming up with the Swiss AC Immune to develop a new minimally invasive Tau diagnostic assay for early diagnosis of Alzheimer’s disease. Alzheimer’s disease has a new case every three seconds, totaling up to 9.9 million new cases of dementia every year. To combat this, AC Immune will […]

September 28, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 26 May 2015

L’Oreal is Bioprinting Human Skin to Stop Animal Testing

A huge improvement could shake the cosmetic testing field very soon. L’Oreal, the French world leader in beauty cosmetics, mostly known for its make-up and hair care products, has just started a partnership with Organovo to print human skin. The amazing thing here is that L’Oreal has already been thinking about giving priority to human skin tests […]

May 26, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 17 May 2015

The Miracle Berry which Hacks your Taste Buds to Replace Sugar

Can you name a fruit capable of disturbing your taste buds? For up to two hours, the red miracle berry can transform sour foods like lemon or vinegar, in an amazing sweet taste. It’s a very interesting berry because of its non-caloric property for anti-obesity and anti-diabetes use. This miracle berry that grows in West Africa contains Miraculin, […]

May 17, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 2 May 2015

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

PlugMed has been awarded €2 million of funding, as part of the World Innovation Challenge organized by the French Ministry of Industry. It will enable the company to speed up the Geroneph project that aims at developing an innovative device in the treatment of kidney failure. Nowadays, dialysis is used by more than two million people […]

May 2, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Apr 2015

Desktop Genetics launches a new Gene Editing Platform

Desktop Genetics has just launched the DeskGen Platform for gene editing. It combines elements of the Company’s earlier tools, and allows researchers to design genome editing vectors and cloning strategies optimized to their own laboratories and experimental needs. The DeskGen platform gives life scientists the power to expertly design optimized genome editing experiments in any cell […]

April 25, 2015 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us